International Journal of *Molecular Sciences*

MDPI

**Supplementary Table 1.** Characteristics of 47 studies included in previously published meta-analyses

| Technique | Meta-analyses | Ref. No. | First author | Year | Country | Study design | Patients with NAFLD (n) | Mean age (years) | Mean BMI ($m/kg^2$) | Male sex, n (%) | Histological score | Noninvasive methods |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VCTE | Xiao | 1 | Wong | 2008 | Hong Kong | Prospective | 34 | Unclear | Unclear | Unclear | Brunt | M probe |
| | Kwok, Jiang | 2 | Yoneda | 2008 | Japan | Prospective | 97 | 51.8 | 26.6 | 40 (41.2%) | Brunt | M probe |
| | Xiao | 3 | Friedrich-Rust | 2010 | Germany | Unclear | 50 | 44 | 29 | 27 (54%) | Kleiner | M probe, XL probe |
| | Kwok, Xiao, Jiang | 4 | Lupsor | 2010 | Romania | Prospective | 72 | 42 | 28.71 | 51 (70.8%) | Brunt | 5-MHz ultrasound transducer probe |
| | Kwok, Jiang | 5 | Myers | 2010 | Canada | Unclear | 50 | Unclear | Unclear | Unclear | Kleiner | M probe |
| | Kwok, Xiao, Jiang | 6 | Wong | 2010 | France/ Hong Kong | Unclear | 246 | 51 | 28 | 135 (54.9%) | Kleiner | M probe, AST/ALT ratio, APRI, BARD score, FIB-4, NFS |
| | Kwok, Jiang | 7 | Yoneda | 2010 | Japan | Unclear | 54 | 50.6 | Male, 28.2 Female, 26.2 | 25 (46.3%) | Brunt | M probe, pSWE, hyaluronic acids, type IV collagen 7S domain |
| | Kwok, Xiao, Jiang | 8 | Gaia | 2011 | Italy | Unclear | 72 | 48 | 27.5 | 52 (72.2%) | Brunt | M probe |
| | Kwok, Xiao | 9 | Petta | 2011 | Italy | Unclear | 146 | 44.1 | 29.1 | 104 (71%) | Kleiner | M probe |
| | Xiao, Jiang | 10 | Myers | 2012 | Canada | Prospective | 127 | Unclear | Unclear | Unclear | Kleiner | M probe, XL probe |
| | Xiao | 11 | Wong | 2012 | France /Hong Kong | Unclear | 193 | Unclear | Unclear | Unclear | Unclear | M probe, XL probe |
| | Xiao | 12 | Alkhouri | 2013 | Italy | Unclear | 67 (children) | Unclear | Unclear | 46 (68.7%) | Kleiner | S probe |
| | Xiao | 13 | Frossard | 2013 | Switzerland | Prospective | Unclear | Unclear | Unclear | Unclear | Metavir | M probe, AST/ALT ratio, APRI, FIB-4 |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | Kwok, Xiao, Jiang | 14 | Kumar | 2013 | India | Unclear | 120 | 39.1 | 26.1 | 90 (75%) | Kleiner | M probe, AST/ALT ratio, APRI, BARD score, FIB-4, NFS |
| | Xiao | 15 | Mahadeva | 2013 | Malaysia | Unclear | 131 | 49.9 | Unclear | 69 (52.7%) | Kleiner | M probe, APRI |
| | Xiao | 16 | Aykut | 2014 | Turkey | Unclear | 88 | 46 | 30.3 | 50 (56.8%) | Kleiner | M probe, XL probe, FibroMeter™ NAFLD, NFS |
| | Xiao | 17 | Naveau | 2014 | France | Prospective | 100 | 42.5 | 42.3 | 19 (19%) | Kleiner | M probe, XL probe |
| | Xiao | 18 | Chan | 2015 | Malaysia | Prospective | 147 | 50.5 | 29.3 | 80 (54.4%) | Kleiner | M probe, NFS |
| | Xiao | 19 | Petta | 2015 | Italy | Unclear | 253 | 45.2 | 29.1 | 177 (70%) | Kleiner | M probe |
| | Xiao | 20 | Petta | 2015 | Italy | Retrospective | 321 | Unclear | Unclear | Unclear | Kleiner | M probe, AST/ALT ratio, APRI, BARD score, FIB-4, NFS |
| | Jiang | 21 | Attia | 2016 | Germany | Prospective | 97 | 50 | 31 | 46 (47.4%) | Kleiner | M probe, XL probe, pSWE |
| | Xiao | 22 | Boursier | 2016 | France | Unclear | 452 | 55.9 | 31.1 | 271 (60.0%) | Kleiner | M probe, APRI, BARD score, FIB-4, FibroMeter$^{NAFLD}$, FibroMeter$^{V2G}$, FibroTest, NFS, Hepascore |
| | Jiang | 23 | Cassinotto | 2016 | France | Prospective | 291 | 56.7 | 32.1 | 172 (59.1%) | Kleiner | M probe, pSWE, 2D-SWE |
| | Xiao, Jiang | 24 | Imajo | 2016 | Japan | Unclear | 142 | 57.5 | 28.1 | 81 (57.0%) | Brunt | M probe, MRE |
| pSWE | Liu, Jiang, Lin | 25 | Osaki | 2010 | Japan | Unclear | 23 | Unclear | Unclear | Unclear | Brunt | pSWE |
| | Kwok, Jiang | 7 | Yoneda | 2010 | Japan | As above. | | | | | | |
| | Liu, Jiang, Lin | 26 | Palmeri | 2011 | USA | Retrospective/ Prospective | 172 | Unclear | Unclear | 65 (37.8%) | Kleiner | pSWE, APRI |
| | Liu, Lin | 27 | Friedrich-Rust | 2012 | Germany | Unclear | 57 | 45 | 28 | 30 (52.6%) | Kleiner | M probe, XL probe, pSWE |
| | Liu, Lin | 28 | Guzmán-Aroca | 2012 | Spain | Prospective | 32 | 43.7 | Male, 44.3 Female, 45.1 | 18 (56.3%) | Brunt, Matteoni | pSWE |
| | Liu, Jiang | 29 | Cassinotto | 2013 | France | Prospective | Unclear | Unclear | Unclear | Unclear | Kleiner | M probe, XL probe, pSWE, |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | FibroTest |
| | Liu, Jiang, Lin | 30 | Fierbinteanu Braticevici | 2013 | Romania | Unclear | 64 | Unclear | Unclear | Unclear | Unclear | pSWE |
| | Jiang | - | Zhang Da-kun and Yang | 2014 | Not in PubMed. | | | | | | |
| | Lin | 31 | Guerra | 2015 | Brazil | Unclear | 7 | Unclear | Unclear | Unclear | Metavir | pSWE |
| | Lin | 32 | Karlas | 2015 | Germany | Unclear | 41 | 45.7 | 46 | 13 (32%) | Kleiner | M probe, XL probe, pSWE, ELF |
| | Jiang | - | Li | 2016 | Not in PubMed. | | | | | | |
| | Jiang, Lin | 21 | Attia | 2016 | Germany | As above. | | | | | |
| | Jiang | 23 | Cassinotto | 2016 | France | As above. | | | | | |
| | Lin | 33 | Cui | 2016 | USA | Prospective | 125 | 48.9 | 31.8 | 57 (45.6%) | Kleiner | pSWE, MRE |
| | Lin | 34 | Harris | 2016 | Australia | Retrospective | Unclear | Unclear | Unclear | Unclear | Metavir | pSWE |
| | Lin | 35 | Lee | 2017 | Korea | Prospective | 94 | 55.5 | 27.1 | 41 (43.6%) | Kleiner | M probe, pSWE, 2D-SWE |
| MRE | Sigh | 36 | Yin | 2007 | USA | Unclear | 10 | Unclear | Unclear | Unclear | Brunt | MRE |
| | Sigh | 37 | Asbach | 2008 | Germany | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | MRE |
| | Sigh | 38 | Asbach | 2010 | Germany | Prospective | 8 | Unclear | Unclear | Unclear | Desmet | MRE |
| | Sigh | 39 | Chen | 2011 | USA | Retrospective | 58 | 51.5 | 38.3 | 10 (17.2%) | Brunt | MRE |
| | Sigh | 40 | Wang | 2011 | USA | Prospective | 8 | Unclear | Unclear | Unclear | Brunt | MRE |
| | Sigh | 41 | Godfrey | 2012 | UK | Unclear | 7 | Unclear | Unclear | Unclear | Kleiner | MRE |
| | Sigh | 42 | Rustogi | 2012 | USA | Retrospective | 1 | Unclear | Unclear | Unclear | Brunt | MRE |
| | Xiao | 43 | Kim | 2013 | Korea | Retrospective | 142 | 52.8 | 36.32 | 38 (26.8%) | Kleiner | MRE, AST/ALT ratio, APRI, BARD score, FIB-4, NFS, Simple panel |
| | Sigh, Xiao | 44 | Loomba | 2014 | USA | Prospective | 117 | 50.1 | 32.4 | 51 (43.6%) | Kleiner | MRE |
| | Xiao | 45 | Cui | 2015 | USA | Prospective | 102 | 51.3 | 31.7 | 60 (58.8%) | Kleiner | MRE, AST/ALT ratio, APRI, Bonacini CDS, BARD score, FIB-4, Lok index, NASH CRN model, NFS |

| | | | | | | |
|---|---|---|---|---|---|---|
| | Xiao | 33 | Cui | 2016 | USA | As above. |
| | Xiao | 24 | Imajo | 2016 | Japan | As above. |

NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; VCTE, vibration-controlled transient elastography; pSWE, point shear wave elastography; 2D-SWE; two-dimensional SWE; MRE, magnetic resonance elastography; APRI, aspartate aminotransferase-to-platelet ratio index; Bonacini CDS, Bonacini cirrhosis discriminant score; ELF, enhanced liver function score; FIB-4, fibrosis-4 index; NASH CRN model, Nonalcoholic Steatohepatitis Clinical Research Network model; NFS, non-alcoholic fatty liver disease fibrosis score.

**References**

1. Wong, G.L.; Wong, V.W.; Choi, P.C.; Chan, A.W.; Chum, R.H.; Chan, H.K.; Lau, K.K.; Chim, A.M.; Yiu, K.K.; Chan, F.K.; et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. *Clin Gastroenterol Hepatol* **2008**, *6*, 1027–1035.
2. Yoneda, M.; Yoneda, M.; Mawatari, H.; Fujita, K.; Endo, H.; Iida, H.; Nozaki, Y.; Yonemitsu, K.; Higurashi, T.; Takahashi, H.; et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). *Dig Liver Dis* **2008**, *40*, 371–378.
3. Friedrich-Rust, M.; Hadji-Hosseini, H.; Kriener, S.; Herrmann, E.; Sircar, I.; Kau, A.; Zeuzem, S.; Bojunga, J. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. *Eur Radiol* **2010**, *20*, 2390–2396.
4. Lupsor, M.; Badea, R.; Stefanescu, H.; Grigorescu, M.; Serban, A.; Radu, C.; Crişan, D.; Sparchez, Z.; Iancu, S.; Maniu, A. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. *J Gastrointestin Liver Dis* **2010**, *19*, 53–60.
5. Myers, R.P.; Elkashab, M.; Ma, M.; Crotty, P.; Pomier-Layrargues, G. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. *Can J Gastroenterol* **2010**, *24*, 153986.
6. Wong, V.W.; Vergniol, J.; Wong, G.L.; Foucher, J.; Chan, H.L.; Le Bail, B.; Choi, P.C.; Kowo, M.; Chan, A.W.; Merrouche, W.; et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology* **2010**, *51*, 454–462.
7. Yoneda, M.; Suzuki, K.; Kato, S.; Fujita, K.; Nozaki, Y.; Hosono, K.; Saito, S.; Nakajima, A. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. *Radiology* **2010**, *256*, 640–647.
8. Gaia, S.; Carenzi, S.; Barilli, A.L.; Bugianesi, E.; Smedile, A.; Brunello, F.; Marzano, A.; Rizzetto, M. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. *J Hepatol* **2011**, *54*, 64–71.
9. Petta, S.; Di Marco, V.; Cammà, C.; Butera, G.; Cabibi, D.; Craxì, A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. *Aliment Pharmacol Ther* **2011**, *33*, 1350–1360.
10. Myers, R.P.; Pomier-Layrargues, G.; Kirsch, R.; Pollett, A.; Duarte-Rojo, A.; Wong, D.; Beaton, M.; Levstik, M.; Crotty, P.; Elkashab, M. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. *Hepatology* **2012**, *55*, 199–208.
11. Wong, V.W.; Vergniol, J.; Wong, G.L.; Foucher, J.; Chan, A.W.; Chermak, F.; Choi, P.C.; Merrouche, W.; Chu, S.H.; Pesque, S.; et al Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. *Am J Gastroenterol* **2012**, *107*, 1862–1871.

12. Alkhouri, N.; Sedki, E.; Alisi, A.; Lopez, R.; Pinzani, M.; Feldstein, A.E.; Nobili, V. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. *Liver Int* **2013**, *33*, 79–85.
13. Frossard, J.L.; Giostra, E.; Rubbia-Brandt, L.; Hadengue, A.; Spahr, L. The role of transient elastography in the detection of liver disease in patients with chronic pancreatitis. *Liver Int* **2013**, *33*, 1121–1127.
14. Kumar, R.; Rastogi, A.; Sharma, M.K.; Bhatia, V.; Tyagi, P.; Sharma, P.; Garg, H.; Chandan Kumar, K.N.; Bihari, C.; Sarin, S.K. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. *Dig Dis Sci* **2013**, *58*, 265–274.
15. Mahadeva, S.; Mahfudz, A.S.; Vijayanathan, A.; Goh, K.L.; Kulenthran, A.; Cheah, P.L. Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease. *J Dig Dis* **2013**, *14*, 604–610.
16. Aykut, U.E.; Akyuz, U.; Yesil, A.; Eren, F.; Gerin, F.; Ergelen, R.; Celikel, C.A.; Yilmaz, Y. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. *Scand J Gastroenterol* **2014**, *49*, 1343–1348.
17. Naveau, S.; Lamouri, K.; Pourcher, G.; Njiké-Nakseu, M.; Ferretti, S.; Courie, R.; Tranchart, H.; Ghinoiu, M.; Balian, A.; Prévot, S.; et al. The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD. *Obes Surg* **2014**, *24*, 1693–1701.
18. Chan, W.K.; Nik Mustapha, N.R.; Mahadeva, S. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis. *Hepatol Int* **2015**, *9*, 594–602.
19. Petta, S.; Maida, M.; Macaluso, F.S.; Di Marco, V.; Cammà, C.; Cabibi, D.; Craxì, A. The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. *Hepatology* **2015**, *62*, 1101–1110.
20. Petta, S.; Vanni, E.; Bugianesi, E.; Di Marco, V.; Cammà, C.; Cabibi, D.; Mezzabotta, L.; Craxì, A. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. *Liver Int* **2015**, *35*, 1566–1573.
21. Attia, D.; Bantel, H.; Lenzen, H.; Manns, M.P.; Gebel, M.J.; Potthoff, A. Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients. *Aliment Pharmacol Ther* **2016**, *44*, 366–379.
22. Boursier, J.; Vergniol, J.; Guillet, A.; Hiriart, J.B.; Lannes, A.; Le Bail, B.; Michalak, S.; Chermak, F.; Bertrais, S.; Foucher, J.; et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. *J Hepatol* **2016**, *65*, 570–578.
23. Cassinotto, C.; Boursier, J.; de Lédinghen, V.; Lebigot, J.; Lapuyade, B.; Cales, P.; Hiriart, J.-B.; Michalak, S.; Bail, B.L.; Cartier, V.; et al. Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. *Hepatology* **2016**, *63*, 1817–1827.
24. Imajo, K.; Kessoku, T.; Honda, Y.; Tomeno, W.; Ogawa, Y.; Mawatari, H.; Fujita, K.; Yoneda, M.; Taguri, M.; Hyogo, H.; et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. *Gastroenterology* **2016**, *150*, 626–637.e7.
25. Osaki, A.; Kubota, T.; Suda, T.; Igarashi, M.; Nagasaki, K.; Tsuchiya, A.; Yano, M.; Tamura, Y.; Takamura, M.; Kawai, H.; et al. Shear wave velocity is a useful marker for managing nonalcoholic steatohepatitis. *World J Gastroenterol* **2010**, *16*, 2918–2925.
26. Palmeri, M.L.; Wang, M.H.; Rouze, N.C.; Abdelmalek, M.F.; Guy, C.D.; Moser, B.; Diehl, A.M.; Nightingale, K.R. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. *J Hepatol* **2011**, *55*, 666–672.
27. Friedrich-Rust, M.; Romen, D.; Vermehren, J.; Kriener, S.; Sadet, D.; Herrmann, E.; Zeuzem, S.; Bojunga, J. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. *Eur J Radiol* **2012**, *81*, e325–e331.
28. Guzmán-Aroca, F.; Frutos-Bernal, M.D.; Bas, A.; Luján-Mompeán, J.A.; Reus, M.; Berná-Serna Jde, D.; Parrilla, P. Detection of non-alcoholic steatohepatitis in patients with morbid obesity before bariatric surgery: preliminary evaluation with acoustic radiation force impulse imaging. *Eur Radiol* **2012**, *22*, 2525–2532.

29. Cassinotto, C.; Lapuyade, B.; Aït-Ali, A.; Vergniol, J.; Gaye, D.; Foucher, J.; Bailacq-Auder, C.; Chermak, F.; Le Bail, B.; de Lédinghen, V. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography—comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease. *Radiology* **2013**, *269*, 283–292.
30. Fierbinteanu Braticevici, C.; Sporea, I.; Panaitescu, E.; Tribus, L. Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease. *Ultrasound Med Biol* **2013**, *39*, 1942–1950.
31. Guerra, J.A.; Trippia, M.; Pissaia, A.; Teixeira, B.C.; Ivantes, C.A. Acoustic radiation force impulse is equivalent to liver biopsy to evaluate liver fibrosis in patients with chronic hepatitis C and nonalcoholic fatty liver disease. *Arq Gastroenterol* **2015**, *52*, 234–238.
32. Karlas, T.; Dietrich, A.; Peter, V.; Wittekind, C.; Lichtinghagen, R.; Garnov, N.; Linder, N.; Schaudinn, A.; Busse, H.; Prettin, C.; et al. Evaluation of transient elastography, acoustic radiation force impulse imaging (ARFI), and enhanced liver function (ELF) score for detection of fibrosis in morbidly obese patients. *PloS One* **2015**, *10*, e0141649.
33. Cui, J.; Heba, E.; Hernandez, C.; Haufe, W.; Hooker, J.; Andre, M.P.; Valasek, M.A.; Aryafar, H.; Sirlin, C.B.; Loomba, R. Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study. *Hepatology* **2016**, *63*, 453–461.
34. Harris, N.; Nadebaum, D.; Christie, M.; Gorelik, A.; Nicoll, A.; Sood, S.; Gibson, R. Acoustic radiation force impulse accuracy and the impact of hepatic steatosis on liver fibrosis staging. *J Med Imaging Radiat Oncol* **2016**, *60*, 587–592.
35. Lee, M.S.; Bae, J.M.; Joo, S.K.; Woo, H.; Lee, D.H.; Jung, Y.J.; Kim, B.G.; Lee, K.L.; Kim, W. Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. *PloS One* **2017**, *12*, e0188321.
36. Yin, M.; Talwalkar, J.A.; Glaser, K.J.; Manduca, A.; Grimm, R.C.; Rossman, P.J.; Fidler, J.L.; Ehman, R.L. Assessment of hepatic fibrosis with magnetic resonance elastography. *Clin Gastroenterol Hepatol* **2007**, *5*, 1207–1213.e2.
37. Asbach, P.; Klatt, D.; Hamhaber, U.; Braun, J.; Somasundaram, R.; Hamm, B.; Sack, I. Assessment of liver viscoelasticity using multifrequency MR elastography. *Magn Reson Med* **2008**, *60*, 373–379.
38. Asbach, P.; Klatt, D.; Schlosser, B.; Biermer, M.; Muche, M.; Rieger, A.; Loddenkemper, C.; Somasundaram, R.; Berg, T.; Hamm, B.; et al. Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography. *Radiology* **2010**, *257*, 80–86.
39. Chen, J.; Talwalkar, J.A.; Yin, M.; Glaser, K.J.; Sanderson, S.O.; Ehman, R.L. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. *Radiology* **2011**, *259*, 749–756.
40. Wang, Y.; Ganger, D.R.; Levitsky, J.; Sternick, L.A.; McCarthy, R.J.; Chen, Z.E.; Fasanati, C.W.; Bolster, B.; Shah, S.; Zuehlsdorff, S.; et al. Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. *AJR Am J Roentgenol* **2011**, *196*, 553–561.
41. Godfrey, E.M.; Patterson, A.J.; Priest, A.N.; Davies, S.E.; Joubert, I.; Krishnan, A.S.; Griffin, N.; Shaw, A.S.; Alexander, G.J.; Allison, M.E.; et al. A comparison of MR elastography and 31P MR spectroscopy with histological staging of liver fibrosis. *Eur Radiol* **2012**, *22*, 2790–2797.
42. Rustogi, R.; Horowitz, J.; Harmath, C.; Wang, Y.; Chalian, H.; Ganger, D.R.; Chen, Z.E.; Bolster, B.D. Jr.; Shah, S.; Miller, F.H. Accuracy of MR elastography and anatomic MR imaging features in the diagnosis of severe hepatic fibrosis and cirrhosis. *J Magn Reson Imaging* **2012**, *35*, 1356–1364.
43. Kim, D.; Kim, W.R.; Talwalkar, J.A.; Kim, H.J.; Ehman, R.L. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. *Radiology* **2013**, *268*, 411–419.
44. Loomba, R.; Wolfson, T.; Ang, B.; Hooker, J.; Behling, C.; Peterson, M.; Valasek, M.; Lin, G.; Brenner, D.; Gamst, A.; et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. *Hepatology* **2014**, *60*, 1920–1928.

45. Cui, J.; Ang, B.; Haufe, W.; Hernandez, C.; Verna, E.C.; Sirlin, C.B.; Loomba, R. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. *Aliment Pharmacol Ther* **2015**, *41*, 1271–1280.